Cardiovascular Disease and Migraine: Are the New Treatments Safe? - Current Pain and Headache Reports
Source : https://link.springer.com/article/10.1007/s11916-022-01064-4
Purpose of Review The authors present data on cardiovascular safety for the new acute and preventive migraine treatments including ditans, gepants, and calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) alongside...
Summary: Long-term data is still needed, and prescribers should ensure patients are aware of the limitations of our knowledge at this time, while still offering these effective and well-tolerated treatment options.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrMore data is needed to answer this but so important to sort out.
-
Dr Hamid3yrNeed more data - there is insufficient evidence that gepants and CGRP mAbs should be contraindicated in those with cardiovascular disease
Show More Comments
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update - The Journal of Headache and Pain
Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01431-x
Background A previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway to prevent migraine. Since then, randomized controlled trials (RCTs)...
Conclusion: Monoclonal antibodies targeting the CGRP pathway are recommended for migraine prevention as they are effective and safe also in the long-term.
-
Dr Hamid3yrMonoclonal antibodies targeting the CGRP pathway is good option for migraine headaches
-
Migraine Connect3yrMany neurologists and others voice concern about the time and challenge of getting Prior Authorization requests approved. What are your thoughts? Do you have any tips? Here is an intriguing Show More
Show More Comments
Elucidating the relationship between migraine risk and brain structure using genetic data - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35735024/
Migraine is a highly common and debilitating disorder that often affects individuals in their most productive years of life. Previous studies have identified both genetic variants and brain morphometry differences...
Conclusion: We leveraged the power of large genome-wide association studies to show evidence of shared genetic pathways that jointly influence migraine risk and several brain structures, suggesting that altered brain morphometry in individuals with high migraine risk may be genetically mediated. Further interrogation of these results showed...
-
Migraine Connect3yrThanks, [~Huma--Sheikh--huma927@ ] and [~Dr--Hamid--ayeshahameed09@ ] for your input! Do you think the findings of these types of studies will contribute to personalized-medicine approaches in the treatment of migraine?
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThe entire brain is involved in migraine, this is good to break down.
Show More Comments
Therapies targeting CGRP signaling for medication overuse headache - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35674079/
Purpose of review: Medication overuse headache (MOH) affects more than 60 million individuals worldwide causing enormous personal and social burden. Only repurposed drugs are available for MOH that share limited...
Summary: The available data indicate that anti-CGRP mAbs represent a good mechanism-based and disease-specific therapeutical option with for MOH as long as detoxification and additional nonpharmaceutical interventions are operated. Future research should focus on long-term-controlled trials in MOH populations exclusively.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis is really important to address.
Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35687795/
doi: 10.1002/brb3.2662. Online ahead of print. 1 Department of Neurology and Centre for Translational Neuro- and Behavioural Sciences (C-TNBS), West German Headache Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany....
Conclusion: A mandatory break in CGRP (pathway) monoclonal antibody therapy had a negative short-term impact on migraine patients.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrI wonder if this is necessary to do.
-
Migraine Connect3yrKey Points • Source: Brain and Behavior • Conclusions: “A mandatory break in CGRP (pathway) monoclonal antibody therapy had a negative short-term impact on migraine patients.” • The investigators assessed clinical data from 46 migraine patients: Show More